Polyacrylamide Antibody Formulations for Interface Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Antibodies in biopharmaceutical formulations tend to aggregate at interfaces, leading to stability issues and requiring low concentration formulations, which necessitate lengthy intravenous administration, limiting their use in resource-limited settings and high-concentration therapeutic applications.
Innovation Solution
Incorporation of polyacrylamide-based copolymers as stabilizing excipients in antibody formulations prevents interfacial adsorption, maintaining antibody stability and allowing for high-concentration subcutaneous administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If antibody concentration is increased in formulation, then therapeutic efficacy is improved, but aggregation at interfaces increases and stability deteriorates
Solution Approach 1:
The patent introduces polyacrylamide-based copolymers as intermediary substances that preferentially adsorb to interfaces (air-water, glass-water, rubber-water), creating a protective barrier that prevents antibody molecules from contacting and aggregating at these interfaces. This mediator approach allows high antibody concentrations to be maintained without the stability issues that would normally occur.
Solution Approach 2:
The invention changes the chemical and physical parameters of the formulation by incorporating specific polyacrylamide-based copolymers with controlled molecular weights and compositions. These parameter changes modify the interfacial properties and protein-polymer interaction characteristics, enabling stable high-concentration formulations that would otherwise aggregate.
2Stability of the object's composition
If low concentration formulation is used to maintain stability, then aggregation is reduced, but administration volume increases and patient burden increases
Solution Approach 1:
The polyacrylamide-based copolymers act as intermediaries that enable high-concentration formulations to remain stable, thereby reducing the total administration volume and time required for therapeutic effect without causing aggregation. This resolves the trade-off between concentration and administration burden.
3Stability of the object's composition
If polyoxyethylene-based surfactants are used to prevent aggregation, then interface adsorption is reduced, but critical micelle concentration is reached and formulation destabilizes
Solution Approach 1:
The patent replaces polyoxyethylene-based surfactants with polyacrylamide-based copolymers that do not form micelles at relevant concentrations. The new excipients provide stable interface protection without the concentration-dependent destabilization caused by micelle formation, effectively replacing a problematic substance with a superior alternative.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polyacrylamide-based copolymers stabilize antibodies at high concentrations, preventing aggregation and maintaining binding activity, enabling subcutaneous injection and reducing patient burden.
Implementation Method 1
These polyacrylamide-based copolymers can be generally applied to confer a substantial stability benefit to high concentration compositions of a variety of antibodies, by precluding adsorption of the antibody to the interfaces of the composition
Data Source
AI summary
Polyacrylamide-based copolymers act as stabilizing excipients in formulations of antibody biopharmaceutical agents without interacting directly with the antibody or altering its pharmacokinetic properties. The polyacrylamide-based copolymers confer a substantial stability benefit to high concentration compositions of a variety of antibodies by precluding adsorption of the antibody to the interfaces of the composition, preventing undesirable aggregation events and maintaining the binding activity of the antibody. Such antibody compositions are useful in methods of administering the composition to a subject.